Off-label injectable advertising — FDA rules for masseter, TMJ, migraine, hyperhidrosis and the education-versus-promotion distinction

Off-label use versus off-label promotion — the distinction that structures everything

The FDA does not regulate the practice of medicine. A licensed physician in the United States may prescribe an FDA-approved product for a use not listed in its labelling — an off-label use — as an exercise of clinical judgement within the practice of medicine. This is well settled in FDA policy and repeatedly stated in agency guidance and public communications. Aesthetic injectables are among the most common categories where off-label use is standard clinical practice — masseter injection for jaw slimming has been used for decades even though it is not an FDA-approved indication for any US-marketed neurotoxin.

What the FDA does regulate is the promotion of a prescription drug. Under 21 USC 331 and 352 of the Federal Food, Drug, and Cosmetic Act, a drug is misbranded if its labelling — which the FDA interprets broadly to include advertising — is false or misleading, or if it recommends a use for which the product lacks adequate directions and adequate warnings. A drug promoted for an off-label use is treated as misbranded because the labelling on file lacks adequate directions for that use. The manufacturer, and anyone acting as the manufacturer's channel, is exposed.

Why aesthetic practices are pulled into a manufacturer framework

An aesthetic practice's advertising can function as a manufacturer's channel when the practice names the product prominently, provides content that mirrors manufacturer messaging, or participates in a coordinated campaign with the manufacturer. Sponsored influencer content, co-branded events with Allergan/AbbVie, Galderma, Merz, Revance or Evolus, and physician-KOL content that a manufacturer helps produce all create the pattern where an aesthetic practice's own website becomes part of the manufacturer's promotional footprint — and the off-label promotion rules attach.

Education versus promotion — how the FDA distinguishes them in practice

The FDA has issued a series of guidances that draw the line between (a) medical communication about scientific information on unapproved uses — which is broadly permissible for manufacturers and clearly permissible for physicians in a patient-care context — and (b) promotion of the unapproved use, which is not permissible for the manufacturer or its channels. The line matters because most aesthetic websites sit somewhere in between and need to actively steer to the compliant side.

Copy patterns the FDA treats as education

• Physician-directed clinical description of the procedure without promotional adjectives ("effective," "safe," "guaranteed").
• A named-provider first-person page in which the physician explains their clinical rationale for offering the off-label use.
• Reference to peer-reviewed literature with a full citation and no editorial promotional gloss.
• Explicit disclosure that the use is off-label and that the discussion is for informational purposes.
• Content that presents alternatives, risks and clinical considerations rather than a call to book.

Copy patterns the FDA treats as promotion

• Naming the product plus a specific unapproved indication in the ad headline or landing-page hero.
• Promise of a specific outcome for the off-label use without disclosure of the off-label status.
• Sponsored influencer content that pairs product name with the off-label use.
• Manufacturer-supplied creative used verbatim in a practice advertisement.
• Comparative claims that position the product as superior for the off-label use.

FDA OPDP and state medical board enforcement — typical patterns

The FDA Office of Prescription Drug Promotion issues Untitled Letters and Warning Letters that name the responsible party (usually the manufacturer, occasionally a distributor or a prominent channel), describe the alleged violation, and require corrective action within a stated period. Corrective actions typically include withdrawing the offending material, running remedial communications to reach the same audience, and revising promotional review processes.

Aesthetic practices seldom appear on the receiving end of an OPDP letter directly — the enforcement footprint tends to reach the manufacturer or the manufacturer-affiliated channel first. Where practice-level exposure concentrates is at the state medical board layer, where misleading-advertising complaints attach directly to the physician's licence.

State medical board layer

• California Business and Professions Code Section 651. Prohibits deceptive or misleading advertising and specifically restricts claims that create unjustified expectations.
• Florida Rule 64B8-11.001. Requires accuracy in physician advertising and permits Board action for misleading claims.
• Texas Medical Board Rule 164.3. Accuracy standard and disclosure requirements on procedural claims.
• New York State Education Law Section 6530. Defines unprofessional conduct to include misleading advertising.

A promotional claim for an off-label use that omits the off-label disclosure is squarely within the misleading-advertising target for these boards. The typical enforcement pattern is a citation, mandatory corrective communications, continuing-education requirements, and in more serious cases licensure discipline.

Where off-label copy sits in the aesthetic marketing stack

Off-label promotion rules interact with every other layer of aesthetic marketing compliance. An influencer promoting an off-label neurotoxin use combines FTC 16 CFR 255 material-connection rules with FDA 21 CFR 202 off-label promotion rules. A HIPAA-scoped landing page for an off-label service combines HIPAA privacy, FDA labelling, FTC substantiation, and state medical board misleading-advertising rules simultaneously.